3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase NA
2
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Leukemia
18
Leukemia, Myeloid, Acute
12
Myelodysplastic Syndromes
10
Lymphoma
10
Burkitt Lymphoma
8
Graft vs Host Disease
7
Lymphoma, Mantle-Cell
6
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Myeloid, Accelerated Phase
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Blast Crisis
6
Recurrence
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Pdgfra-Associated Chronic Eosinophilic Leukemia
5
Myeloproliferative Disorders
5
Myelodysplastic-Myeloproliferative Diseases
5
Lymphoma, Non-Hodgkin
5
Leukemia, Neutrophilic, Chronic
5
Congenital Abnormalities
5
Thrombocythemia, Essential
4
Primary Myelofibrosis
4
Polycythemia Vera
4
Lymphoma, Follicular
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Biphenotypic, Acute
4
Hodgkin Disease
4
Hematologic Neoplasms
4
Neoplasms, Plasma Cell
3
Interventions
pembrolizumab
44
Nivolumab
29
Gemcitabine
28
Paclitaxel
19
Cisplatin
18
Ipilimumab
15
Carboplatin
14
Cyclophosphamide
13
Capecitabine
12
Dexamethasone
10
Bevacizumab
10
cemiplimab
9
Irinotecan
9
Docetaxel
9
Albumin-Bound Paclitaxel
9
130-nm albumin-bound paclitaxel
9
spartalizumab
8
Pemetrexed
8
Sorafenib
7
Rituximab
7
Cetuximab
7
fludarabine
6
Temozolomide
6
Taxes
6
Radiotherapy
6
Leucovorin
6
Fluorouracil
6
Azacitidine
6
Ascorbic Acid
6
lenvatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms
×
Methotrexate
×
Clear all
NCT02912676
2020-04-15
TEAM
Rigshospitalet, Denmark
Phase 1/2
Completed
30 enrolled